Week Ending April 11, 2022

Universal Hepatitis C Screening During Pregnancy Detects More Cases
“Universal hepatitis C virus (HCV) screening for all pregnant women led to a 7.5-fold increase in the number of treatable cases detected, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2022).”

Accessible Care Key to Treating Hepatitis C in People Who Inject Drugs
“Among participants who had hepatitis C and who injected drugs, those treated at a non-stigmatizing “accessible care” treatment center co-located with a syringe service program (SSP) were nearly three times more likely to be cured of the infectious disease compared with those referred out to local clinicians through patient navigation, according to a randomized clinical trial led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, NYU Grossman School of Medicine, and the CUNY Graduate School of Public Health and Health Policy. It is estimated that more than 80 percent of people with hepatitis C in the United States presently inject drugs, so the results suggest that expanding and supporting the accessible care model could be instrumental in eliminating the disease.”

Causes and Risk Factors of Hepatitis D
“Hepatitis D is a virus that affects the liver. There’s no vaccine or specific treatment for hepatitis D. You can’t get a hepatitis D infection unless you already have a hepatitis B infection or are infected with both viruses at the same time.”

These steps may identify patients eligible for shorter DAA therapy
“Measuring hepatitis C virus at baseline and on days 7 and 14 of therapy — and eliminating blood draws on days 2 and 28 — can identify patients who may be eligible for a shorter duration of therapy, according to a study.”

Health Matters with Fresh Start: The truth about Hepatitis C: Separating fact from fiction
“Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) and ranges from a mild illness lasting a few weeks to a serious, lifelong illness.  Hepatitis C can either be “acute” meaning a new infection, or “chronic” meaning a lifelong infection.”

Financial Health Spotlight: What’s the Cost of Not Treating Hep C?
“Hepatitis C is a viral infection of the liver that can be cured with treatment. But while medications are extremely effective at treating hepatitis C, they come at a high cost. Research has shown that a course of hepatitis C treatment can come with a five-figure price tag, depending on the drug. However, skipping treatment for hepatitis C may actually end up being even more costly for both your wallet and your quality of life. The condition can lead to serious liver damage and put you at risk of other conditions, all of which can be expensive to manage and interfere with your ability to work.”

Hepatitis C Widespread but Rarely Treated in Postpartum Medicaid Beneficiaries with Opioid Use Disorder
“Nearly a third of pregnant Medicaid beneficiaries who have opioid use disorder and are screened for hepatitis C test positive for the potentially deadly, liver-destroying virus, according to new findings made by a research consortium led by University of Pittsburgh School of Public Health scientists.“

Identification of NS5B Resistance-Associated Mutations in Hepatitis C Virus Circulating in Treatment Naïve Vietnamese Patients
“Treatment of HCV infection with peginterferon and ribavirin results in a low sustained virologic response rate, but has a number of undesirable adverse effects. Direct-acting antivirals (DAAs) offer a high efficacy, low risk, and a short treatment time. However, the existence of resistance-associated mutations, particularly in the NS5B polymerase, can attenuate the efficacy of DAAs. The objective of this study was to identify amino acid changes in the NS5B gene linked to DAA resistance in treatment-naive Vietnamese chronic hepatitis C patients.”

Retention on antiretroviral therapy in person with HIV and viral hepatitis coinfection in Ethiopia: a retrospective cohort study
“HIV coinfection with viral hepatitis B (HBV) or viral hepatitis C (HCV) is not uncommon in Ethiopia. Although the coinfections are presumed to interfere with antiretroviral treatment (ART), this is not widely studied in Sub-Saharan African settings. This study was conducted to determine ART retention in persons coinfected with HIV + HBV or HIV + HCV.”